引言表皮生长因子受体（EGFR）突变是非小细胞肺癌（NSCLC）的重要驱动因素，EGFR 酪氨酸激酶抑制剂（TKI）已成为其标准一线治疗。然而，患者在接受 TKI 治疗后普遍出现获得性耐药，导致疾病进展，后续治疗选择有限且疗效欠佳。铂类化疗作为患者 EGFR TKI 治疗进展后的主要手段，中位无进展生存期（PFS）仅 2.8-4.9 ...

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

近年来，针对罕见靶点突变阳性NSCLC的治疗策略持续取得重要突破，呈现药物选择不断丰富的可喜局面。其中部分靶向疗法已获批应用于临床，更多药物则正处于临床试验阶段，并在多项国际前沿研究中显示出令人鼓舞的疗效信号，为患者带来了新的生存希望。

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

Retrospective review of 33,850 molecularly profiled ovarian cancer samples from real-world patients who underwent next-generation sequencing (NGS) of DNA between 2016 and 2025. EGFR-mutated cases were ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight ...

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...